These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7059462)

  • 41. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
    Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
    Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of the toxicity of radiomimetic alkylating agents in rats by thiol pretreatment. V. The effect of thiol pretreatment on the anti-tumour action of Merophan.
    Connors TA; Jenney A; Whisson ME
    Biochem Pharmacol; 1965 Nov; 14(11):1681-3. PubMed ID: 5867521
    [No Abstract]   [Full Text] [Related]  

  • 44. Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
    Anderson WK
    Cancer Res; 1982 Jun; 42(6):2168-70. PubMed ID: 6280852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Enzyme variations in tumors following carcinostatic therapy of human colonic tumors in golden hamsters].
    Goldenberg H; Goldenberg DM
    Enzymol Biol Clin (Basel); 1969; 10(6):507-16. PubMed ID: 4187971
    [No Abstract]   [Full Text] [Related]  

  • 46. Enzyme activated anti-tumour agents--III. Hydrolysis of conjugates of p-hydroxyaniline mustard in aqueous solution.
    Workman P; Double JA; Wilman DE
    Biochem Pharmacol; 1976 Nov; 25(21):2347-50. PubMed ID: 999722
    [No Abstract]   [Full Text] [Related]  

  • 47. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
    Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
    Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
    Fodstad O; Aamdal S; Pihl A; Boyd MR
    Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limitations of the human tumour xenograft system in individual patient drug sensitivity testing.
    Bailey MJ; Jones AJ; Shorthouse AJ; Raghaven D; Selby P; Gibbs J; Peckham MJ
    Br J Cancer; 1984 Nov; 50(5):721-4. PubMed ID: 6498071
    [No Abstract]   [Full Text] [Related]  

  • 50. Attempt to increase the effect of regional chemotherapy in experimental tumours by procaine.
    Godál A; Medzihradský J; Knotek J; Ujházy V
    Neoplasma; 1969; 16(4):389-92. PubMed ID: 5344224
    [No Abstract]   [Full Text] [Related]  

  • 51. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).
    Ciomei M; Pastori W; Capolongo L; Geroni C; Melegaro G; Pennella G; Grandi M
    Br J Cancer; 1995 Dec; 72(6):1504-8. PubMed ID: 8519667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative antitumor effects of peptichemio and other alkylating agents.
    Schmid FA; Banks SE; Stock CC
    Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
    [No Abstract]   [Full Text] [Related]  

  • 54. 3-N,N-bis(2-chloroethylamino)p-toluic acid, a new cytostatic drug active in cancer.
    Dobre V; Maltezeanu G
    Cancer Chemother Rep; 1970 Oct; 54(5):319-23. PubMed ID: 5514620
    [No Abstract]   [Full Text] [Related]  

  • 55. [Effects of a synthetic peptide on the cytotoxic activity of the lymphocytes of animals with tumors].
    Landolfo S; Pugliese A
    G Batteriol Virol Immunol; 1975; 68(7-12):240-6. PubMed ID: 1234592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ability of CEA blood levels to reflect tumour burden: a study in a human xenograft model.
    Quayle JB
    Br J Cancer; 1982 Aug; 46(2):220-7. PubMed ID: 7150474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
    Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Macromolecular derivatives of N,N-di-(2-chloroethyl)-4-phenylene diamine mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy.
    Soyez H; Seymour LW; Schacht E
    J Control Release; 1999 Feb; 57(2):187-96. PubMed ID: 9971901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colon tumor: enzymology of the neoplastic program.
    Weber G; Kizaki H; Tzeng D; Shiotani T; Olah E
    Life Sci; 1978 Aug; 23(7):729-36. PubMed ID: 692291
    [No Abstract]   [Full Text] [Related]  

  • 60. Anti-tumor effects of 5-hydroxytryptamine (5-HT) are not entirely attributable to its effects on tumor vasculature.
    Jenkins DC; Wilkinson J; Lindon JC; Farrant RD; Carpenter TA; Stables JN; Topley P; Lindstead DJ; Holmes LS
    Int J Radiat Biol; 1991; 60(1-2):243-8. PubMed ID: 1677978
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.